Home / People / Stefan Lehr
Portrait ofStefan Lehr

Stefan Lehr

Partner
Rechtsanwalt

CMS Hasche Sigle
Neue Mainzer Straße 2–4
60311 Frankfurt
Germany
Languages German, English, French

Stefan Lehr specialises in merger control and has many years of experience advising on cross-border merger control proceedings. He represents his clients – among those companies in the machine and plant engineering, automotive supply and tourism sector – in antitrust proceedings before the German and European competition authorities and courts and in antitrust damages actions. His antitrust expertise is often sought in the context of structuring distribution systems and intercorporate co-operations. Stefan also advises companies in different industry sectors on warranty and liability issues as well as on licencing and other agreements related to distribution, procurement and production.

He joined CMS in 1995 and became a partner in 1999. In 2001 and 2002, he was seconded to law firms in London and New York.

more less

Listed for Competition / Antitrust

Deutschlands beste Anwälte 2023 – Handelsblatt in Kooperation mit Best Lawyers

Listed for Mergers and Acquisitions

Deutschlands beste Anwälte 2023 – Handelsblatt in Kooperation mit Best Lawyers

Relevant experience

  • Advising Wärtsilä Corporation on joint ventures with China State Shipbuilding Corporation
  • Advising Telefónica/O2 on the acquisition of E-Plus from KPN
  • Advising Hill-Rom on the acquisition of Trumpf Medical
  • Advising a capacitor manufacturer in a European Commission investigation into alleged price fixing
  • Advising a German tour operator in a European Commission investigation on alleged discriminatory practices
more less

Memberships & Roles

  • Studienvereinigung Kartellrecht e. V.
  • Kartellrechtsforum Frankfurt
more less

Publications

  • German American Chamber of Commerce, New York (Co-Autor: Riesenkampff), European Cartel Law 2008
  • Kartellrecht Loewenheim/Meessen/Riesenkampff, Kommentierung Art. 2 und 3 Fusionskontrollverordnung und §§ 37, 39-43 GWG, C.H.Beck 2008
  • Kommentierung Art.2 und 3 Fusionskontrollverordnung und §§37, 39-43 GWG, Loewenheim/Messen/Riesenkampff 2005
  • Schwerer Stand für das VW-Gesetz vor dem EuGH, Börsen-Zeitung 2003
more less

Education

  • Law studies in Frankfurt and Cologne
more less
27/10/2023
JUVE Awards 2023: CMS recognised as Law Firm of the Year for Antitrust
Berlin – International commercial law firm CMS Germany was recognised yesterday evening as Law Firm of the Year for Antitrust at the JUVE Awards 2023. The JUVE Awards are regarded as among the most...

Feed

26/03/2024
CMS advises sellers of Cardior Pharmaceuticals on potential acquisition...
Munich – CMS advises the sellers of Cardior Pharmaceuticals in the potential acquisition of the company by Novo Nordisk. Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved. The agreement includes Cardior’s lead compound CDR132L, currently in phase 2 clinical development for the treatment of heart failure. The closing of the acquisition is subject to receipt of applicable regulatory approvals and other customary conditions. It is expected to happen in the second quarter of 2024.A CMS team headed by Lead Partners Stefan-Ulrich Müller, Dr Tilman Weichert and Jörg Schrade advised the sellers of Cardior Pharmaceuticals on all legal aspects of the transaction. Cardior Pharmaceuticals GmbH, based in Hannover, Germany, is a leading clinical-stage bio­phar­ma­ceut­ic­al company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. CMS Germany Stefan-Ulrich Müller, Lead Partner Dr Tilman Weichert, Lead Partner Dr Michael Wangemann, Partner Dr Kai Wallisch, Partner Dr Thomas Mühl, Principal Coun­sel Se­basti­an Hummel, Senior As­so­ci­ate Vikt­or­ia Barthel, Senior As­so­ci­ate Mar­i­elouise Emmer, Senior Associate Dr Carl-Friedrich Thoma, Senior Associate Dr Stefan Kühl, Senior Associate Dr Alexander Weinhold, Senior Associate Maria Kucher, Associate Jonas Ohmann, Associate Dr Josephine Doll, Associate Dr Christian Seeburger, Associate Sonja Schanze, Associate, all Corporate/M&A Dr Marie-Luisa Loheide, Associate, Private Clients Jörg Schrade, Lead Partner Eduard Kosavtsev, Senior Associate, both Tax Stefan Lehr, Partner, Antitrust, Competition & Trade Stefan Lüft, Partner, IP Dr Benedikt Forschner, Partner, Labor, Employment & Pensions Dr Markus Kaulartz, Partner Dr Fiona Savary, Counsel Dr Felix Glocker, Senior Associate, all TMC Dr Tilman Niedermaier, Partner Susanne Schwalb, Partner, both Dispute ResolutionPress Con­tact presse@cms-hs. com
18/03/2024
CMS advises biotechnology firm Tubulis on EUR 128 million Series B2 financing...
Munich – Munich-based biotech company Tubulis has announced the successful completion of its extended and over-subscribed Series B2 round of financing, which raised EUR 128 million. This latest round was led by EQT Life Sciences and Swiss biotech investor Nextech Invest Ltd., representing funds that it manages. Other investors included US funds Frazier Life Sciences and Deep Track Capital along with all the existing investors, including Andera Partners, BioMedPartners, Fund+, Bayern Kapital’s ScaleUp-Fonds Bayern, Evotec, coparion, Seventure Partners, Occident and High-Tech Gründerfonds (HTGF). Tubulis will use the capital raised to develop the firm’s pipeline of next-generation antibody-drug conjugates (ADCs). The aim is also to complete the first clinical evaluation of its two drug candidates and to drive forward the company’s planned US expansion.A CMS team headed by partner Stefan-Ulrich Müller advised Tubulis on all legal aspects of the Series B2 financing. The team led by Stefan-Ulrich Müller has been advising Tubulis for several years now, including on the preceding EUR 60 million Series B round of financing. This work is another excellent example of the wide-ranging advisory services that CMS offers in the Lifesciences & Healthcare sector. CMS Germany Stefan-Ulrich Müller, Lead Part­ner Se­basti­an Hummel, Senior Associate Maria Kucher, Associate, all Corporate/M&A, Venture Capital Stefan Lüft, Partner, Intellectual Property Jörg Schrade, Partner, Tax Stefan Lehr, Partner, Antitrust, Competition & TradePress Con­tact presse@cms-hs. com
29/02/2024
CMS advises Bobst Group on sale of minority stake in BHS Group
Frankfurt am Main – Bobst Group SA, a leading global supplier of equipment and services to the packaging industry, has sold its long-standing minority stake of 30% in BHS Corrugated Maschinen- und Anlagenbau GmbH. The transaction sees the majority shareholder, BWV-Well­pap­pen­maschinen Vertriebs-GmbH, acquiring the equity interest back from Bobst Group SA and increasing its majority stake in the BHS Group.A CMS team headed by Dr Hendrik Hirsch advised Bobst Group SA on all legal aspects of the transaction. Ahead of the transaction, CMS also provided Bobst Group SA with comprehensive corporate law advice on its minority stake. Bobst Group SA is based in the Swiss city of Lausanne and is one of the world’s leading suppliers of equipment and services for substrate production, printing and processing. Its customers include the label, flexible packaging, folding box and corrugated board industries. The group generated sales of around CHF 2 billion in 2023. BHS Corrugated Maschinen- und Anlagenbau GmbH is a global supplier of mechanical engineering, plant engineering, lifecycle services and digital solutions for the corrugated board industry. It is headquartered in the Bavarian town of Weiherhammer. CMS Germany Dr Hendrik Hirsch, Partner Dr Maximilian Stark, Senior Associate, both Corporate/M&A Dr Jan Schepke, Partner Dr Armin Dürrschmidt, Partner Marcus Weiler, Senior Associate Dr Philipp Koch, Counsel, all Corporate Stefan Lehr, Partner, Antitrust, Competition & TradePress Con­tact presse@cms-hs. com
28/02/2024
CMS advises Bruker on the multi-jur­is­dic­tion­al acquisition of ELITech,...
Frankfurt/Main – Bruker has agreed to acquire ELITechGroup, a provider of specialty in vitro diagnostic (IVD) systems, from TecFin S.à r.l., a controlled affiliate of PAI Partners, a pre-eminent private equity firm, for EUR 870 million in cash, excluding the carved out ELITech clinical chemistry business. The transaction is expected to close in the second quarter of 2024, subject to regulatory approvals and other customary closing conditions.A team of CMS Germany headed by lead partner Dr Hendrik Hirsch acted as lead transaction counsel on this landmark transaction for Bruker's MDx business covering all M&A aspects of the transaction, IVDR and other regulatory aspects, antitrust and FDI filings, the carve out of the clinical chemistry business and support on the employee consultation processes in France and the Netherlands. ELITechGroup, with over 500 employees and over 40 active patents, develops and commercializes innovative, proprietary molecular diagnostic (MDx) systems and assays, as well as niche biomedical systems and microbiology products. Its molecular diagnostic business accounts for the majority of the to-be-acquired revenues and provides the unique sample-to-answer (S2A) instruments InGenius® and Be-Genius® in the mid-to-high throughput MDx category with PCR diagnostic assays for infections and diseases. ELITechGroup, excluding the clinical chemistry business, achieved approximately EUR 150 million in revenues in 2023. ELITechGroup generates the majority of its revenues from Europe, with significant business also in North and Latin America. Its major R&D and production sites are in Italy, the United States, France and Germany. CMS Germany Dr Hendrik Hirsch, Partner, Co-Lead Dr Jacob Siebert, Partner, Co-Lead Dr Dirk Baukholt, Principal Counsel Dr Berrit Roth-Mingram, Counsel Dr Maximilian Stark, Senior Associate, all Corporate/M&A Dr Roland Wiring, Partner Lukas Burgdorff, Associate Noah Rodenkirchen, Associate, all Regulatory & Lifesciences Dr Thomas Hirse, Part­ner Se­basti­an Vautz, Senior Associate Lisa Dietrich, Associate, all IP Dr Michael Bauer, Partner Stefan Lehr, Partner Kai Neuhaus, Partner Moritz Pottek, Counsel Dr. Denis Schlimpert, Counsel Kirsten Baubkus-Gerard, Senior Associate David Rappenglück, As­so­ci­ate Be­ne­dikt Christian Voss, Associate, all Antitrust, Competition & Trade Dr Thomas de la Motte, Partner Dr Markus Pfaff, Partner Dr André Frischemeier, Partner Hatice Aykel, Counsel Alisa Brehm, Senior Associate Thomas Schaak, Senior Associate Dr Sait Dogan, Associate, all Banking & Finance  Dr André Lippert, Part­ner Con­stan­ze Schweidtmann, Associate, both Real Estate & Public Dr Boris Alles, Partner Dr Theresa Kipp, Senior Associate, both Labor, Employment & Pensions CMS France Benoît Gomel, Partner Vincent Desbenoit, Associate Dylan Allali, all Corporate/M&A Caroline Froger-Michon, Partner Aurélie Parchet, As­so­ci­ate Ca­m­ille Baumgarten, Associate Sophie Yin, all Em­ploy­ment Claire Vannini, Partner Eleni Moraïtou, Coun­sel Lilia-Ori­ana Dif, Associate Ariane Rolin, all Competition & EU  Jean-Bap­tiste Thiénot, Partner Anaïs Arnal, Associate, both Intellectual Property Laurine Mayer, Associate, TMC Alexandre Chazot, Counsel, Banking & Fin­ance  Thi­erry Granier, Partner Renaud Grob, Partner, both Tax Arnaud Valverde, Senior Associate, Real Estate Olivier Kuhn, Partner Cécile Rebiffé, Counsel Mylène Garrouste, all Dispute Res­ol­u­tion Kawthar Ben Khelil, Coun­sel Jean-Pierre Malili, Associate, both Public law/In­fra­struc­ture CMS Italy Massimo Trentino, Partner, Corporate/M&A Maria Letizia Patania, Partner, Lifescience & Healthcare Gian Marco Lettieri, Senior Associate, Employment & Pensions Giulio Poggioli, Counsel Valerio Giuseppe Daniele, As­so­ci­ate Francesca Durante, Junior As­so­ci­ate  Arianna Toccaceli, Junior Associate, all Banking & Finance CMS Luxembourg Gérard Maitrejean, Partner Miruna Poenaru, Coun­sel Max­imili­an Helfgen, Associate, all Corporate/M&A CMS UK Jack Letson, Partner Lindsay McAllister, Associate, both Corporate/M&A David Dennis, Partner, Commercial CMS Netherlands Pieter van Duijvenvoorde, Partner Robert Jong, both Corporate/M&A Nigel Henssen Fleur van Assendelft de Coningh, both Employment Edmon Oude Elferink, Partner Marijke van der Vossen, both Antitrust, Competition & Trade CMS Serbia Radivoje Petrikić, Partner Mila Drljević, both Corporate/M&A CMS Austria Dieter Zandler, Partner Vanessa Horaceck, both Competition & EU CMS Ukraine Maria Orlyk, Partner Diana Valyeyeva CMS Turkiye Döne Yalçın, Partner Arcan Kemahlı,  Sa­ba­hat­tin Öztemiz Taner ElmasPress Con­tact presse@cms-hs. com
16/02/2024
CMS advises shareholder of vision tools on the sale of a majority stake...
Frankfurt/Main - The shareholder of vision tools rental and distributions gmbh, a leading company for audiovisual technical equipment in Europe, has sold a majority stake in the company to the Dutch The Rental Group B.V., a portfolio company of Capital A Investment Partners. The aim of the strategic partnership of the AV rental service company vision tools is to utilize the synergies created by the merger and thus to consolidate sustainable growth and its market position. The parties have agreed not to disclose details of the transaction.A CMS team headed by Dr Joachim Dietrich advised the shareholder of vision tools on all legal aspects of this transaction. Press Con­tact presse@cms-hs. com   
16/01/2024
CMS advises listed mobility solutions specialist Össur on acquisition of...
Frankfurt/Main – Össur, Nasdaq Copenhagen listed leading global provider of innovative mobility solutions, acquired all shares of privately owned Fior & Gentz, a Germany based leading European manufacturer of lower limb neuro orthotic components. Fior & Gentz develops and distributes knee and ankle orthotic joints to create innovative custom-made orthotic solutions for patients with gait impairments due to neurological conditions. The acquisition of Fior & Gentz represents an attractive opportunity for Össur to enter the fast-growing neuro orthotics market. The transaction volume amounts to around EUR 100 million plus an earn-out of up to EUR 20 million. The payment consists of cash as well as of newly issued, listed shares of Icelandic Össur hf. to the sellers of Fior & Gentz. An international CMS team led by Dr Heike Wagner and Dr Tobias Kilian advised Össur comprehensively on all legal aspects also in connection with this transaction. CMS Germany Dr Heike Wagner, Partner Dr Tobias Kilian, Of Counsel, both Lead Dr Reiner Thieme, As­so­ci­ate Nath­alie Amrhen, Associate, all Corporate / M&A Jörg Schrade, Partner Eduard Kosavtsev, Senior Associate, both Tax Dr Roland Wiring, Partner Dr Siham Hidar, Senior Associate  Noah Rodenkirchen, Associate, all Regulatory & Lifesciences Dr Stefan Lehr, Partner, Antitrust, Competition & Trade Dr Dirk Smielick, Principal Counsel, IP Prof Dr Malte Grützmacher, Partner, IT Dr Boris Alles, Partner Dela Herr, Associate, both Labor, Employment & Pensions  Dr Franz Maurer, Counsel Wiebke Westermann, Associate, both Real Estate & Public CMS Netherlands Roman Tarlavski, Part­ner Mar­cel­lina Rietvelt, Associate, both Corporate / M&A Martijn van der Bie, Partner Gieneke van Nierop, Counsel, both Corporate / Notaries CMS Norway Nicolas Jorn Brunet, Partner Tuva Svare, Associate, both Corporate / M&A Henrik Nordling, Partner, Antitrust, Competition & TradePress Con­tact presse@cms-hs. com
20/11/2023
CMS advises shareholders of MVC Mobile Video­Com­mu­nic­a­tion on international...
Frankfurt/Main – MVC Mobile Video­Com­mu­nic­a­tion GmbH, based in Kronberg (Taunus), and the Finnish company Elisa Videra are joining forces as part of a share swap. Elisa Videra is an internationally active...
27/10/2023
JUVE Awards 2023: CMS recognised as Law Firm of the Year for Antitrust
Berlin – International commercial law firm CMS Germany was recognised yesterday evening as Law Firm of the Year for Antitrust at the JUVE Awards 2023. The JUVE Awards are regarded as among the most...
12/10/2023
CMS advises Phoenix Tower International on acquisition of tele­com­mu­nic­a­tions...
Munich - Global wireless communications infrastructure provider Phoenix Tower International is acquiring the German subsidiary of Dutch NOVEC BV. Berlin-based Novec GmbH is an independent provider of...
28/07/2023
Encavis AG helps drive expansion of renewable energy in Germany with aid...
Frankfurt/Main – CMS has advised MDAX-listed wind farm and solar plant operator Encavis AG (“Encavis”) on a joint venture with Freiburg-based energy utility badenova AG & Co. KG (“baden­ova”)...
06/07/2023
CMS advises fitness technology provider EGYM on €207 million comprehensive...
Munich – German fitness technology and corporate fitness provider EGYM has received €207 million in fresh capital from US investor Affinity Partners and existing investors Mayfair Equity Partners...
13/06/2023
CMS advises fund managed by private equity firm ECM on acquisition of ONE...
Frankfurt/Main – German Equity Partners V (“GEP V” or the “Fund”) has taken an equity interest in the Düs­sel­dorf-based talent acquisition platform ONE HIRING Group (“1H”) through a partnership...